NEW YORK (AP) -- Canadian drugmaker Oncolytics Biotech Inc. said Wednesday it will continue with a late-stage clinical trial of its experimental cancer drug Reolysin.
Oncolytics is testing Reolysin as a treatment for head and neck cancers. The company said an independent analysis of the safety of Reolysin was conducted after 80 patients were treated in the study. Based on that review, the monitoring committee said the study should continue. Oncolytics plans to enroll 100 to 400 more patients.
The trial compares a combination of Reolysin with two chemotherapy drugs, carboplatin and paclitaxel, to the two chemotherapy drugs and a placebo. Oncolytics is testing the drug on patients who were not helped by a previous round of chemotherapy.
The Calgary-based company is also testing Reolysin as a treatment for lung, prostate, colorectal, and skin cancers.
Shares of Oncolytics Biotech gained a penny to $3.31 in morning trading.
- Oncolytics Biotech